Andrew McConaghie

The big pharma is tapping into Muna's MiND-MAP platform to gain extra validation for its own early-stage work in Alzheimer's and other neurodegenerative conditions.

Overall survival data presented at ASH and filed with the US FDA puts Blenrep on course for a comeback – something that GSK's oncology leader said he had never really doubted.

Phase III success will help expand the CD19-targeting drug’s niche in lymphoma, as Incyte looks for growth beyond the coming expiry of its blockbuster Jakafi.

Roche is highlighting the fixed-duration dosing benefits of Lunsumio and Columvi over AbbVie/Genmab's Epkinly in B-cell lymphomas as they fight for market dominance. However, the speed at which the companies complete Phase III studies could also be a deciding factor.

The biotech's lead candidate now looks approvable as the first new localized prostate cancer treatment in 20 years – allowing Candel to raise much-needed funds – but a filing must wait

The oncology drug development veteran has been hired by former colleague Daniel O'Day as Gilead looks to improve its R&D hit rate.

Looking to diversify in the face of competition to its main earner, Ruconest, the Netherlands-based Pharming may have bagged itself a rare disease bargain with Abliva.

Adam Steensberg talked to Scrip about his firm’s vision for obesity treatment, Zealand’s independence from neighbor Novo Nordisk, and the hunt for a partner for its amylin candidate, petrelintide.

The Phase IIb failure was expected, but Roche believes consistent trends towards efficacy could be confirmed with ongoing open-label studies, leaving life in the program yet.

The antisense oligonucleotide specialist is ready to launch its rare disease therapy Tryngolza but could face competition from a more potent rival by mid-2025.